Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20201105 | 0.94 | USP2 (0.41) | USP2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12946062 | 0.92 | USP2 (0.40) | USP2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19199025 | 0.92 | TSHR (0.36) | USP2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18535491 | 0.92 | USP2 (0.40) | USP2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13638472 | 0.88 | TSHR (0.39) | USP2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8470445 | 0.88 | TSHR (0.39) | USP2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8369489 | 0.88 | — | — | |
| SCHEMBL13890773 | 0.86 | TSHR (0.38) | USP2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1375292 | 0.86 | TSHR (0.38) | USP2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20047143 | 0.86 | TSHR (0.38) | USP2TSHRCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| WO-2023018648-A1 | PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM | GENENTECH, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| EP-3851435-A1 | MEDICAL APPLICATION OF PYRIMIDINE SULFONAMIDES DERIVATIVES | Chinese PLA General Hospital (CN) | 2021-07-21 | — | — | EP | disclosed |
| WO-2017136403-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | USP2 3851/4885TSHR 4764/4885CYP1A2 4661/4885 |
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | USP2 2863/4885TSHR 2206/4885CYP1A2 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.